epocrates logo
epocrates logo
epocrates logo
  • 0

Interaction Check

epocrates logo

Sign in to access our clinical decision support tools

Sign in Create Account

Selected Drugs Clear All

  • remove Besremi (ropeginterferon alfa-2b-njft)
    ropeginterferon alfa-2b
  • remove Septra
    sulfamethoxazole/ trimethoprim

multicheck MultiCheck Results - 1 Interaction

Smiley face Smiley face

Avoid/Use Alternative
Smiley face Smiley face Besremi (ropeginterferon alfa-2b-njft) (ropeginterferon alfa-2b) + Septra (sulfamethoxazole/ trimethoprim)

Avoid/Use Alternative

ropeginterferon alfa-2b + trimethoprim

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

Additional Considerations
Smiley face Smiley face ropeginterferon alfa-2b in Besremi (ropeginterferon alfa-2b-njft)

caution advised with narrow therapeutic index drugs; interferons may suppress CYP450 enzyme activity, resulting in incr. exposure of CYP substrates
Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information